<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41939">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02009124</url>
  </required_header>
  <id_info>
    <org_study_id>NGBSI-03</org_study_id>
    <nct_id>NCT02009124</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy in Spinal Cord Injury</brief_title>
  <official_title>Open Label Study of Autologous Bone Marrow Mononuclear Cells in Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurogen Brain and Spine Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurogen Brain and Spine Institute</source>
  <oversight_info>
    <authority>India: Indian Council of Medical Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the effect of stem cell therapy on common symptoms in
      patients with spinal cord injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autologous bone marrow mononuclear cells are administered intrathecally by a standard
      procedure followed by vigorous rehabilitation therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in clinical symptoms of spinal cord injury after 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional independence measure (FIM)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>It is a standard objective scale used for functional evaluation of the spinal cord injury patients. Its reliability and validity has been well established. It will be marked by a certified occupational therapy expert before the intervention and 6 months after the intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous bone marrow mononuclear cell transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Stem cell therapy is not done for this group of spinal cord injury patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous bone marrow mononuclear cell transplantation</intervention_name>
    <description>Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure</description>
    <arm_group_label>Stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed cases of any type of spinal cord injury

          -  age above 12 months.

        Exclusion Criteria:

          -  presence of acute infections such as Human immunodeficiency virus/Hepatitis B
             Virus/Hepatitis C Virus

          -  malignancies

          -  bleeding tendencies

          -  pneumonia

          -  renal failure

          -  severe liver dysfunction

          -  severe anemia [Hemoglobin &lt; 8]

          -  any bone marrow disorder

          -  space occupying lesion in brain

          -  other acute medical conditions such as respiratory infection and pyrexia.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alok K Sharma, MS,MCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurogen Brain and Spine Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alok K Sharma, M.S, M.Ch</last_name>
    <phone>02225281610</phone>
    <email>alok276@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurogen brain and spine institute</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400071</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alok k Sharma, M.S, M.Ch.</last_name>
      <phone>91-22-25281610</phone>
      <email>alok276@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Kumar AA, Kumar SR, Narayanan R, Arul K, Baskaran M. Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: A phase I/II clinical safety and primary efficacy data. Exp Clin Transplant. 2009 Dec;7(4):241-8.</citation>
    <PMID>20353375</PMID>
  </reference>
  <reference>
    <citation>Yoshihara T, Ohta M, Itokazu Y, Matsumoto N, Dezawa M, Suzuki Y, Taguchi A, Watanabe Y, Adachi Y, Ikehara S, Sugimoto H, Ide C. Neuroprotective effect of bone marrow-derived mononuclear cells promoting functional recovery from spinal cord injury. J Neurotrauma. 2007 Jun;24(6):1026-36.</citation>
    <PMID>17600518</PMID>
  </reference>
  <reference>
    <citation>Sharma A, Gokulchandran N, Chopra G, Kulkarni P, Lohia M, Badhe P, Jacob VC. Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life. Cell Transplant. 2012;21 Suppl 1:S79-90. doi: 10.3727/096368912X633798.</citation>
    <PMID>22507683</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 6, 2013</lastchanged_date>
  <firstreceived_date>December 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal cord injury</keyword>
  <keyword>stem cell therapy</keyword>
  <keyword>bone marrow</keyword>
  <keyword>mononuclear cells</keyword>
  <keyword>autologous</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
